Atypical severe immune-related adverse effects resulting from sequenced immunotherapy in melanoma

Melanoma Res. 2015 Apr;25(2):178-9. doi: 10.1097/CMR.0000000000000132.

Abstract

We report unusual severe toxicity in three patients treated at our institution with sequenced immunotherapy for metastatic melanoma. These three patients illustrate the unusual potential toxicity of sequential administration of anti-programmed cell death 1 followed by ipilimumab, and the need for careful monitoring of these toxicities associated with sequential immunotherapies. Data from forthcoming trials and national databases such as MELBASE, recently implemented in France, will be helpful in providing further insights into the risks and benefits of sequential immunotherapy schedules.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Monoclonal / adverse effects*
  • Antibodies, Monoclonal, Humanized / adverse effects*
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects*
  • CTLA-4 Antigen / antagonists & inhibitors
  • CTLA-4 Antigen / immunology
  • Humans
  • Immune System Diseases / chemically induced*
  • Immune System Diseases / diagnosis
  • Immune System Diseases / drug therapy
  • Immune System Diseases / immunology
  • Immunotherapy / adverse effects*
  • Ipilimumab
  • Melanoma / drug therapy*
  • Melanoma / immunology
  • Nivolumab
  • Programmed Cell Death 1 Receptor / antagonists & inhibitors
  • Programmed Cell Death 1 Receptor / immunology
  • Skin Neoplasms / drug therapy*
  • Skin Neoplasms / immunology
  • Steroids / therapeutic use
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • CTLA-4 Antigen
  • CTLA4 protein, human
  • Ipilimumab
  • PDCD1 protein, human
  • Programmed Cell Death 1 Receptor
  • Steroids
  • Nivolumab
  • pembrolizumab